Q-omics provides the consensus-scored NOL11 profile across patient tissues and cancer cell-line models. NOL11 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NOL11 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, NOL11 protein abundance shows 34,454 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where NOL11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOL11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOL11 survival associations across molecular data types. NOL11 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOL11 RNA expression–survival associations across cancer types. High NOL11 expression shows unfavorable associations in LIHC, ACC, KIRP and CESC, but favorable associations in READ and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NOL11 RNA expression.
This table summarizes NOL11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NOL11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOL11 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, BLCA, KIRP and LIHC. The HNSC box plot shows higher NOL11 RNA expression in tumor versus normal tissue (log2 FC = +1.013, t-test p < 0.001).
This table shows molecular features associated with NOL11 in patient tissues and cancer cell lines. In patient samples, NOL11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NOL11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
